- Home
- DXCM vs BIIB Comparison
DXCM vs BIIB Comparison
Compare DXCM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | BIIB |
|---|---|---|
| Founded | 1999 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 27.1B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DXCM | BIIB |
|---|---|---|
| Price | $62.47 | $183.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 27 |
| Target Price | $85.33 | ★ $195.00 |
| AVG Volume (30 Days) | ★ 3.4M | 726.6K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.18 | N/A |
| EPS | 2.09 | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $14.48 | N/A |
| Revenue Next Year | $12.39 | N/A |
| P/E Ratio | $29.76 | ★ $20.91 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $54.11 | $110.04 |
| 52 Week High | $89.07 | $202.41 |
Technical Indicators
Market Signals| Indicator | DXCM | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 47.21 |
| Support Level | $54.11 | $181.24 |
| Resistance Level | $69.18 | $184.16 |
| Average True Range (ATR) | 1.94 | 4.38 |
| MACD | -0.30 | 0.12 |
| Stochastic Oscillator | 1.06 | 24.57 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).